Results 191 to 200 of about 9,558 (217)

Dolutegravir–rilpivirine for virological suppression

The Lancet HIV, 2019
Anton L, Pozniak, Jose R, Arribas
openaire   +2 more sources

Suppression of Zika Virus Infection in the Brain by the Antiretroviral Drug Rilpivirine

Molecular Therapy, 2019
Ilker Kudret Sariyer, Eleonora Gianti, Martina Donadoni   +2 more
exaly  

Rilpivirin

2013
openaire   +1 more source

Dolutegravir/rilpivirine

Reactions Weekly, 2019
openaire   +1 more source

Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension

Journal of Controlled Release, 2018
Helen O Mccarthy, Eneko Larrañeta, Courtney Jarrahian   +2 more
exaly  

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)

Journal of Infectious Diseases, 2016
Urvi M Parikh, Akil G A Jackson, David Back   +2 more
exaly  

Carbon quantum dots co-catalyzed with multiwalled carbon nanotubes and silver nanoparticles modified nanosensor for the electrochemical assay of anti-HIV drug Rilpivirine

Sensors and Actuators B: Chemical, 2019
Sevinc Kurbanoglu, Nurgul K Bakirhan, Sibel A Ozkan   +2 more
exaly  

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

Lancet Infectious Diseases, The, 2015
Joseph J Eron
exaly  

Cabotegravir/rilpivirine

Reactions Weekly, 2019
openaire   +1 more source

Agonism of human pregnane X receptor by rilpivirine and etravirine: Comparison with first generation non-nucleoside reverse transcriptase inhibitors

Biochemical Pharmacology, 2013
Aik Jiang Lau, Thomas
exaly